Inferra AI / Company / COLL
Collegium Pharmaceutical, Inc.
COLL · Health Care
Last earnings Aug 6, 2026
Key results
Record Quarterly Net revenuequarter
$188.0 Million
Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year Generated Record
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Growthquarter
Up 29%
Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year Generated Record
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Jornay PM Net revenuequarter
$32.6 Million
Quarterly Jornay PM Net Revenue of $32.6 Million and Grew Prescriptions by 23%
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Year-over-Year Generated Net revenuequarter
$155.4 Million
Year-over-Year Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Revenuequarter
$32.6 million
Generated $32.6 million in Jornay PM net revenue in the 2025 Quarter.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Pain Portfolio Highlights Grew net revenues from pain portfolio to a record $155.4 million in the 2025 Quarter, up 7% year-over-year.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Generated Belbuca net revenue of $52.6 million in the 2025 Quarter, up 1% year-over-year.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Generated Xtampza ER net revenue of $52.6 million, up 18% year-over-year.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Generated Nucynta Franchise net revenue of $46.4 million, up 4% year-over-year.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
AI analysis
Q2 2025 · reported Aug 7, 2025
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
The quarter in charts
Segment mix
Business-unit revenue, as stated
Segment revenue figures as stated in the event record.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Record Quarterly Net revenue | $188.0 Million | — | — |
| Growth | Up 29% | — | — |
| Jornay PM Net revenue | $32.6 Million | — | — |
| Year-over-Year Generated Net revenue | $155.4 Million | — | — |
| Revenue | $32.6 million | — | — |
Guidance · company-stated
Direction: Raised
“Following encouraging performance in the first half of the year, we anticipate a strong back-to-school season and second half of the year for Jornay PM and have raised our full-year revenue guidance accordingly.”
“We delivered another impressive quarter characterized by record quarterly revenue, robust adjusted EBITDA, and significant cash flow generation, leading us to increase our 2025 financial guidance, said Colleen Tupper, Chief Financial Officer.”
Classified from the release's primary full-year outlook statement.
Capital allocation
We will continue to evaluate external opportunities to expand our portfolio through business development and generate shareholder value through our capital deployment strategies, as demonstrated by the recent completion of a $25 million accelerated share repurchase program and the announcement of a new $150 million share repurchase program authorized through the end of 2026.
Corporate Updates In July, the Board of Directors authorized a new share repurchase program to repurchase up to $150 million of common stock through December 31, 2026.
Event summary
Collegium Pharmaceutical, Inc. Q2 2025 — Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year Generated Record
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue — Raised (“raised”)
“Following encouraging performance in the first half of the year, we anticipate a strong back-to-school season and second half of the year for Jornay PM and have raised our full-year revenue guidance accordingly.”
Revenue — Raised (“increase”)
“We delivered another impressive quarter characterized by record quarterly revenue, robust adjusted EBITDA, and significant cash flow generation, leading us to increase our 2025 financial guidance, said Colleen Tupper, Chief Financial Officer.”
Classified from the release's primary full-year outlook statement.
Capital allocation
We will continue to evaluate external opportunities to expand our portfolio through business development and generate shareholder value through our capital deployment strategies, as demonstrated by the recent completion of a $25 million accelerated share repurchase program and the announcement of a new $150 million share repurchase program authorized through the end of 2026.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Corporate Updates In July, the Board of Directors authorized a new share repurchase program to repurchase up to $150 million of common stock through December 31, 2026.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
In July, completed an accelerated share repurchase program returning $25 million of value to shareholders through the repurchase of 0.8 million shares at an average share price of $30.41.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Net debt/adjusted EBITDA is calculated based on financial data provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on August 7, 2025.
SEC original ↗Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
Estimated 2025 net debt/adjusted EBITDA is calculated based on Collegium’s forecast of net debt at year-end 2025, compared to the mid-point of the 2025 guidance ranges provided by Collegium in its press release filed with the SEC on August 7, 2025.
SEC original ↗Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
This financial data assumes no additional debt is incurred.
SEC original ↗Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
Strategy & priorities
We continued to generate strong momentum in the second quarter, driven by sustained execution across our three strategic priorities, including record revenue from Jornay PM, maximizing our pain portfolio, and strategically deploying capital to enhance shareholder value, said Vikram Karnani, President and Chief Executive Officer.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Looking ahead, we are focused on driving additional top- and bottom-line growth as we continue to serve patients living with serious medical conditions.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
We will continue to evaluate external opportunities to expand our portfolio through business development and generate shareholder value through our capital deployment strategies, as demonstrated by the recent completion of a $25 million accelerated share repurchase program and the announcement of a new $150 million share repurchase program authorized through the end of 2026.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Collegium s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Strong track record of using cash generated to fuel highly successful business development opportunities Committed to increasing shareholder value by growing revenues, adjusted EBITDA and strategically deploying capital 2025 expected sales $753M 2024 sales $631M +19% FIVE MARKETED PRODUCTS1 5 Recent Business Highlights – Q2 20251 1.
SEC original ↗Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
Risks & headwinds
The amount and/or frequency of these restructuring expenses are not part of our underlying business; we exclude litigation settlements from adjusted EBITDA, as well as any applicable income items or credit adjustments due to subsequent changes in estimates.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
The Company has not provided a reconciliation of its full-year 2025 guidance for adjusted EBITDA or adjusted operating expenses to the most directly comparable forward-looking GAAP measures, in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K, because the Company is unable to predict, without unreasonable efforts, the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense, acquisition related expense and litigation settlements.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
SEC original ↗Collegium Pharmaceutical, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.
SEC original ↗Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
The amount and/or frequency of these restructuring expenses are not part of our underlying business; • we exclude litigation settlements from adjusted EBITDA, as well as any applicable income items or credit adjustments due to subsequent changes in estimates.
SEC original ↗Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 7, 2025
Legal Proceedings 53 Item 1A.
SEC original ↗Collegium Pharmaceutical, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Earnings deck slides
0 decks with slide viewCollegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Collegium Pharmaceutical, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
33 documents- Q3 2026
- 8-KCOLL
- Q2 2026
- 8-KCOLL
- 8-KCOLL
- 10-QCOLL
- Q1 2026
- 8-K/ACOLL
- 8-KCOLL
- 8-KCOLL
- 8-KCOLL
- 10-QCOLL
- 8-KCOLL
- Q4 2025
- 8-KCOLL
- EX-99COLL
- 8-KCOLL
- 10-KCOLL
- 8-KCOLL
- EX-99COLL
- Q3 2025
- 8-KCOLL
- EX-99COLL
- 8-KCOLL
- 10-QCOLL
- Q2 2025
- 8-KCOLL
- 10-QCOLL
- 8-KCOLL
- Q1 2025
- 8-KCOLL
- 8-KCOLL
- 8-KCOLL
- 10-QCOLL
- Q4 2024
- 8-KCOLL
- 8-KCOLL
- 10-KCOLL
- 8-KCOLL
- 8-KCOLL
- Q3 2024
- 8-K/ACOLL
Earnings releases
12 documentsPresentations
8 documents
Transcripts
0 documentsNo transcripts for Collegium Pharmaceutical, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.